中国患者晚期非小细胞肺癌的治疗：聚焦于埃克替尼。
Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib.
作者信息
Liang Jun-Li, Ren Xiao-Cang, Lin Qiang
机构信息
Department of Radiation Oncology, Hebei Medical University Fourth Hospital, Shijiazhuang, People's Republic of China.
Department of Oncology, North China Petroleum Bureau General Hospital of Hebei Medical University, Renqiu, Hebei Province, People's Republic of China.
出版信息
Onco Targets Ther. 2014 May 16;7:761-70. doi: 10.2147/OTT.S49233. eCollection 2014.
Abstract
Icotinib hydrochloride is an orally administered small-molecule reversible tyrosine kinase inhibitor that has been independently researched and developed and has independent intellectual property rights in the People's Republic of China. Clinical trials have demonstrated that the response to icotinib among advanced non-small-cell lung cancer (NSCLC) patients who received at least one platinum-based chemotherapy regimen was not inferior to gefitinib. Since being launched August 2011 in the People's Republic of China, icotinib has been widely used in clinics, and has become an important treatment option for Chinese patients with advanced NSCLC. The present study presents the Phase I, II, and III clinical trials of icotinib and discusses current clinical applications in the People's Republic of China and future research directions.
摘要
盐酸埃克替尼是一种口服的小分子可逆性酪氨酸激酶抑制剂，在中国自主研发并拥有自主知识产权。临床试验表明，在接受至少一种铂类化疗方案的晚期非小细胞肺癌（NSCLC）患者中，埃克替尼的疗效不劣于吉非替尼。自2011年8月在中国上市以来，埃克替尼已在临床上广泛应用，并已成为中国晚期NSCLC患者的重要治疗选择。本研究介绍了埃克替尼的I期、II期和III期临床试验，并讨论了其在中国目前的临床应用情况及未来的研究方向。
相似文献
1
Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib.中国患者晚期非小细胞肺癌的治疗：聚焦于埃克替尼。
Onco Targets Ther. 2014 May 16;7:761-70. doi: 10.2147/OTT.S49233. eCollection 2014.
2
[Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].[已确定埃克替尼对具有表皮生长因子受体（EGFR）状态的晚期非小细胞肺癌患者的疗效]
Zhongguo Fei Ai Za Zhi. 2013 Mar;16(3):138-43. doi: 10.3779/j.issn.1009-3419.2013.03.04.
3
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.厄洛替尼对比吉非替尼用于经治的晚期非小细胞肺癌（ICOGEN）：一项随机、双盲、III 期非劣效性试验
Lancet Oncol. 2013 Sep;14(10):953-61. doi: 10.1016/S1470-2045(13)70355-3. Epub 2013 Aug 13.
4
Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.盐酸厄洛替尼（BPI-2009H）的 I 期临床研究，一种口服表皮生长因子受体酪氨酸激酶抑制剂，用于晚期非小细胞肺癌和其他实体瘤患者。
Lung Cancer. 2011 Aug;73(2):195-202. doi: 10.1016/j.lungcan.2010.11.007. Epub 2010 Dec 8.
5
Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.厄洛替尼对比全脑放疗用于表皮生长因子受体突变型非小细胞肺癌伴多发脑转移患者（BRAIN）：一项多中心、三期、开放标签、平行、随机对照临床试验。
Lancet Respir Med. 2017 Sep;5(9):707-716. doi: 10.1016/S2213-2600(17)30262-X. Epub 2017 Jul 19.
6
Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status.一线培美曲塞治疗后序贯应用伊可替尼治疗 EGFR 基因状态未知的晚期肺腺癌。
J Thorac Dis. 2014 Jul;6(7):958-64. doi: 10.3978/j.issn.2072-1439.2014.07.18.
7
Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.在中国，吉非替尼、埃克替尼和培美曲塞为基础的化疗作为晚期非小细胞肺癌一线治疗的成本效益分析
Oncotarget. 2017 Feb 7;8(6):9996-10006. doi: 10.18632/oncotarget.14310.
8
Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy.表皮生长因子受体（EGFR）突变的非小细胞肺癌患者接受或不接受埃克替尼巩固治疗的随机辅助化疗
PLoS One. 2015 Oct 16;10(10):e0140794. doi: 10.1371/journal.pone.0140794. eCollection 2015.
9
[Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified].盐酸埃克替尼用于表皮生长因子受体（EGFR）状态明确的晚期非小细胞肺癌患者的临床观察
Zhongguo Fei Ai Za Zhi. 2015 Dec;18(12):734-9. doi: 10.3779/j.issn.1009-3419.2015.12.04.
10
Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer.厄洛替尼对于 EGFR 基因突变的非小细胞肺癌脑转移与吉非替尼同样有效。
BMC Cancer. 2020 Jan 30;20(1):76. doi: 10.1186/s12885-020-6543-y.
引用本文的文献
1
Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance.非小细胞肺癌靶向治疗：药物及耐药机制。
Int J Mol Sci. 2022 Dec 1;23(23):15056. doi: 10.3390/ijms232315056.
2
Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China.中国非小细胞肺癌一线治疗中的免疫疗法：现状与未来方向
Front Oncol. 2021 Nov 25;11:757993. doi: 10.3389/fonc.2021.757993. eCollection 2021.
3
Complete remission following icotinib administration in an advanced ectopic thymic carcinoma patient harbouring the EGFR exon 19 deletion.晚期胸内异位胸腺癌患者 EGFR 外显子 19 缺失，伊可替尼治疗后完全缓解。
J Gene Med. 2021 Jul;23(7):e3340. doi: 10.1002/jgm.3340. Epub 2021 May 5.
4
First-Line EGFR-TKIs Treatment in Stage I Non-Small-Cell Lung Cancer Patients Harboring EGFR Gene Mutations with Postoperative Intrapulmonary Recurrence.表皮生长因子受体酪氨酸激酶抑制剂一线治疗伴有术后肺内复发的Ⅰ期非小细胞肺癌表皮生长因子受体基因突变患者
Cancer Manag Res. 2021 Feb 18;13:1667-1672. doi: 10.2147/CMAR.S292295. eCollection 2021.
5
Effectiveness of EGFR-TKIs in a Patient with Lung Adenocarcinoma Harboring an Fusion.携带融合的肺腺癌患者中 EGFR-TKIs 的疗效。
Oncologist. 2019 Aug;24(8):1027-1030. doi: 10.1634/theoncologist.2018-0732. Epub 2019 May 7.
6
The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: a retrospective analysis.在真实临床环境中，埃克替尼联合化疗对未经治疗的表皮生长因子受体（EGFR）敏感突变非小细胞肺癌的疗效：一项回顾性分析
Onco Targets Ther. 2018 Apr 26;11:2345-2353. doi: 10.2147/OTT.S157755. eCollection 2018.
7
Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation.阿帕替尼联合伊可替尼治疗 EGFR 突变晚期肺腺癌患者获得性伊可替尼耐药的初步研究
Thorac Cancer. 2018 May;9(5):656-661. doi: 10.1111/1759-7714.12624. Epub 2018 Mar 24.
8
A tumor-targeting cRGD-EGFR siRNA conjugate and its anti-tumor effect on glioblastoma in vitro and in vivo.一种肿瘤靶向性cRGD-EGFR siRNA偶联物及其对胶质母细胞瘤的体内外抗肿瘤作用
Drug Deliv. 2017 Nov;24(1):471-481. doi: 10.1080/10717544.2016.1267821.
9
Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.埃克替尼治疗非小细胞肺癌的疗效与安全性：基于15项研究的系统评价与Meta分析
Oncotarget. 2016 Dec 27;7(52):86902-86913. doi: 10.18632/oncotarget.13509.
10
Icotinib versus docetaxel used in lung adenocarcinoma patients who failed platinum-based chemotherapy: a retrospective study.埃克替尼与多西他赛用于铂类化疗失败的肺腺癌患者：一项回顾性研究。
Onco Targets Ther. 2016 Jul 1;9:4037-41. doi: 10.2147/OTT.S99434. eCollection 2016.
本文引用的文献
1
Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.厄洛替尼、吉非替尼、阿法替尼和埃克替尼用于携带EGFR突变的晚期非小细胞肺癌患者的网状Meta分析。
PLoS One. 2014 Feb 12;9(2):e85245. doi: 10.1371/journal.pone.0085245. eCollection 2014.
2
Clinical pharmacokinetics of Icotinib, an anti-cancer drug: evaluation of dose proportionality, food effect, and tolerability in healthy subjects.依西美坦的临床药代动力学：在健康受试者中评估其剂量比例性、食物效应和耐受性。
Cancer Chemother Pharmacol. 2014 Apr;73(4):721-7. doi: 10.1007/s00280-014-2398-8. Epub 2014 Feb 1.
3
4
Dramatic response to high-dose icotinib in a lung adenocarcinoma patient after erlotinib failure.厄洛替尼治疗失败后，高剂量伊可替尼治疗肺腺癌患者获得显著疗效。
Lung Cancer. 2014 Feb;83(2):305-7. doi: 10.1016/j.lungcan.2013.12.002. Epub 2013 Dec 12.
5
[Trend analyses on the differences of lung cancer incidence between gender, area and average age in China during 1989-2008].[1989 - 2008年中国肺癌发病率在性别、地区及平均年龄方面差异的趋势分析]
Zhongguo Fei Ai Za Zhi. 2013 Sep;16(9):445-51. doi: 10.3779/j.issn.1009-3419.2013.09.02.
6
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.厄洛替尼对比吉非替尼用于经治的晚期非小细胞肺癌（ICOGEN）：一项随机、双盲、III 期非劣效性试验
Lancet Oncol. 2013 Sep;14(10):953-61. doi: 10.1016/S1470-2045(13)70355-3. Epub 2013 Aug 13.
7
[Clinical observation of icotinib hydrochloride in first-line therapy for pulmonary adenocarcinoma].盐酸埃克替尼一线治疗肺腺癌的临床观察
Zhongguo Fei Ai Za Zhi. 2013 Jul;16(7):364-8. doi: 10.3779/j.issn.1009-3419.2013.07.06.
8
[Clinical effects for patients with recurrent advanced non-small cell lung cancer treated with icotinib hydrochloride].盐酸埃克替尼治疗复发晚期非小细胞肺癌患者的临床疗效
Zhongguo Fei Ai Za Zhi. 2013 May;16(5):240-5. doi: 10.3779/j.issn.1009-3419.2013.05.05.
9
A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma.一项初步研究：吉西他滨/顺铂序贯联合伊可替尼作为 IIB 期至 IIIA 期非小细胞肺腺癌的诱导治疗。
World J Surg Oncol. 2013 Apr 26;11:96. doi: 10.1186/1477-7819-11-96.
10
Icotinib, a potent and specific EGFR tyrosine kinase inhibitor, inhibits growth of squamous cell carcinoma cell line A431 through negatively regulating AKT signaling.盐酸埃克替尼是一种高效、高选择性的表皮生长因子受体酪氨酸激酶抑制剂，通过负向调控 AKT 信号通路抑制鳞状细胞癌细胞系 A431 的生长。
Biomed Pharmacother. 2013 Jun;67(5):351-6. doi: 10.1016/j.biopha.2013.03.012. Epub 2013 Apr 2.
Zotero 插件